Evidence map›Paper›PMID 36091037›Full record

ArticleFrontiers in immunology2022

The effects of nutrition bio-shield superfood powder on immune system function: A clinical trial study among patients with COVID-19.

Farid Azizi Jalilian, Gheisar Keshavarz, Salman Khazaei, Manije Nezamdoost, Seyed Hamid Hashemi, Mojgan Mamani, Nastaran Ansari, Razieh Amini, Aref Khalkhali, Arghavan Keshavarz and 9 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. The Important Role of Interleukin-2 in COVID-19.Journal of immunology research · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 1 country.

Farid Azizi JalilianResearch Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Gheisar KeshavarzDepartment of Internal Medicine, Ilam University of Medical Sciences, Ilam, Iran.
Salman KhazaeiResearch Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran.
Manije NezamdoostDepartment of Infectious Disease, Farabi Hospital, Iranian Social Security Organization, Mashhad, Iran.
Seyed Hamid HashemiDepartment of Infectious Disease, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Mojgan MamaniDepartment of Infectious Disease, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Nastaran AnsariDepartment of Medical Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Razieh AminiResearch Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Aref KhalkhaliNBS Organic Company, Istanbul, Turkey.
Arghavan KeshavarzFaculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Erfan AyubiSocial Determinants of Health Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
Maryam FazeliDepartment of Medical Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Rashid Heidari MoghadamResearch Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran.
Saeid AlizadehRadiology Department of Sina Hospital, Hamadan, Iran.
Behzad PourhosseinDepartment of Medical Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Ali TeimouriDepartment of Medical Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Fariba KeramatDepartment of Infectious Disease, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Sajad KarampourDepartment of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Mohammadreza KhakzadDepartment of Immunology, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
Hamedan University of Medical Sciences · IRIran University of Medical Sciences · IRIslamic Azad University, Mashhad · IRMedical University of Ilam · IRShahid Beheshti University of Medical Sciences · IRSina Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to evaluate the effects of Nutrition Bio-shield Superfood (NBS) powder on the immune system function and clinical manifestations in patients with COVID-19. We compare the effects of NBS powder on the immune system function and clinical manifestations among two different groups: 1) intervention group receiving standard treatment scheduled according to treatment guidelines plus NBS powder, and 2) control group receiving only the same standard treatment. The serum levels of IL-2, IL-6, IL-17, IFNγ, and TNFα were determined after four weeks of treatment by specific ELISA kits according to the manufacturer's instructions. Finally, the level of immune system stimulation and inflammatory markers were compared at baseline and after intervention in both groups. Data were analyzed using SPSS (version 22). A p-value of ≤ 0.05 was set as significant. A total of 47 patients with COVID-19 (24 patients in the intervention group and 23 patients in the control group) were included in this study. Results showed that the differences in the mean decrease of IL-2, IL-6, and TNF-α in the intervention group in comparison to the control group were 0.93, 10.28, and 8.11 pg/ml, respectively (P<0.001). On the other hand, there was no difference in IL-17, IFNγ, monocytes, eosinophil, and other inflammatory indices between the intervention and control groups. Although NBS powder was able to significantly decrease the levels of some proinflammatory cytokines in patients with COVID-19, however, it is noteworthy that the course of the disease was to large part unaffected by NBS power and there was a reduction independent of treatment. The present study indicates that NBS powder could provide a beneficial anti-inflammatory effect in patients with COVID-19. Hence, NBS in treating patients with COVID-19 shows promise as an adjuvant to the current standard antiviral treatment of such patients. Clinical Trial Registration: https://www.irct.ir, identifier IRCT20200426047206N1.

Indexed as

COVID-19 Drug TreatmentInterleukin-17HumansInterleukin-2Interleukin-6MonocytesPowdersTumor Necrosis Factor-alphaInterleukin-17Interleukin-2Interleukin-6PowdersTumor Necrosis Factor-alphaCOVID-19ELISA - enzyme-linked immunosorbent assayimmunity system functionIrannutrition bio-safety powder

Identifiers

PMID36091037
PMCPMC9458072
OpenAlexW4293072749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.